Efficacy of a Glass Membrane Emulsification Device to Form Mixture of Cisplatin Powder with Lipiodol on Transarterial Therapy for Hepatocellular Carcinoma.
Arterial embolization
Cisplatin
Emulsion
Hepatocellular carcinoma
Lipiodol
Journal
Cardiovascular and interventional radiology
ISSN: 1432-086X
Titre abrégé: Cardiovasc Intervent Radiol
Pays: United States
ID NLM: 8003538
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
22
10
2020
accepted:
23
12
2020
pubmed:
9
1
2021
medline:
29
6
2021
entrez:
8
1
2021
Statut:
ppublish
Résumé
To examine physiochemical characteristics and drug release properties of cisplatin powder and lipiodol mixtures formed by a glass membrane emulsification device compared with a 3-way stopcock. Seven different types of mixtures were evaluated: cisplatin powder and lipiodol directly mixed (suspension), complete cisplatin solution and lipiodol mixed by a 3-way stopcock or the device (emulsion), incomplete cisplatin solution and lipiodol mixed by a 3-way stopcock or the device (solid-in-water emulsion), and contrast material and cisplatin suspension mixed by a 3-way stopcock or the device (solid-in-oil emulsion). The percentages of water-in-oil were 98.08 ± 0.27% in the emulsion formed by the device, while 70.3 ± 4.63% in the emulsion formed by a 3-way stopcock (P = 0.037). Solid-in-water and solid-in-oil emulsions formed by the device showed 98.09 ± 0.38% and 98.70 ± 0.40% of water-in-oil, respectively, whereas both solid-in-water and solid-in-oil emulsions formed by a 3-way stopcock showed 0.00%. Homogenous droplet sizes were shown by using the device. The half release times of cisplatin in the emulsions formed by the device were 197 ± 19, 244 ± 24 and 478 ± 52 min, respectively, which were significantly longer than the emulsion formed by a 3-way stopcock of 8 ± 8 min (P = 0.046-0.050). Suspension showed the longest release time; however, the viscosity was lowest. The glass membrane emulsification device formed almost 100% water-in-oil, whereas 3-way stopcock produced 100% oil-in-water when incomplete solution or suspension was mixed. Slower cisplatin release was shown in the emulsions formed by the device.
Identifiants
pubmed: 33415417
doi: 10.1007/s00270-020-02757-2
pii: 10.1007/s00270-020-02757-2
doi:
Substances chimiques
Antineoplastic Agents
0
Emulsions
0
Ethiodized Oil
8008-53-5
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
766-773Références
Okada S, Okazaki N, Nose H, et al. A phase 2 study of cisplatin in patients with hepatocellular carcinoma. Oncology. 1993;50:22–6.
doi: 10.1159/000227142
Ueno K, Miyazono N, Inoue H, et al. Transcatheter arterial chemoembolization therapy using lodized oil for patients with unresectable hepatocellular carcinoma. Cancer. 2000;88:1574–81.
doi: 10.1002/(SICI)1097-0142(20000401)88:7<1574::AID-CNCR11>3.0.CO;2-8
Moriguchi M, Aramaki T, Tanaka T, Itoh Y. Hepatic arterial infusion chemotherapy: a potential therapeutic option for hepatocellular carcinoma with portal vein tumor thrombus. Liver Cancer. 2018;7:209–10.
doi: 10.1159/000488156
Morimoto K, Sakaguchi H, Tanaka T, et al. Transarterial chemoembolization using cisplatin powder in a rabbit model of liver cancer. Cardiovasc Interv Radiol. 2008;31:981–5.
doi: 10.1007/s00270-008-9367-8
Ikeda K. Recent advances in medical management of hepatocellular carcinoma. Hepatol Res. 2019;49(1):14–32.
doi: 10.1111/hepr.13259
Otsuji K, Takai K, Nishigaki Y, Shimizu S, Hayashi H, Imai K. Efficacy and safety of cisplatin versus miriplatin in transcatheter arterial chemoembolization and transarterial infusion chemotherapy for hepatocellular carcinoma: a randomized controlled trial. Hepatol Res. 2015;45:514–22.
doi: 10.1111/hepr.12376
Terashima T, Yamashita T, Arai K, et al. Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib. Hepatol Res. 2014;44:1179–85.
doi: 10.1111/hepr.12266
Takaki H, Yamakado K, Tsurusaki M, et al. Hepatic arterial infusion chemotherapy with fine-powder cisplatin and iodized-oil suspension in patients with intermediate-stage and advanced-stage (Barcelona Clinic Liver Cancer stage-B or stage-C) hepatocellular carcinoma: multicenter phase-II clinical study. Int J Clin Oncol. 2015;20:745–54.
doi: 10.1007/s10147-014-0773-4
Kasai K, Ushio A, Kasai Y, et al. Therapeutic efficacy of transarterial chemo-embolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma. World J Gastroenterol. 2013;19:2242–8.
doi: 10.3748/wjg.v19.i14.2242
Maeda N, Osuga K, Higashihara H, et al. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion. Cardiovasc Interv Radiol. 2012;35:82–9.
doi: 10.1007/s00270-010-0086-6
Beppu T, Sugimoto K, Shiraki K, et al. Clinical utility of transarterial infusion chemotherapy using cisplatin-lipiodol emulsion for unresectable hepatocellular carcinoma. Anticancer Res. 2012;32:4923–30.
pubmed: 23155261
de Baere T, Dufaux J, Roche A, et al. Circulatory alterations induced by intra-arterial injection of iodized oil and emulsions of iodized oil and doxorubicin: experimental study. Radiology. 1995;194:165–70.
doi: 10.1148/radiology.194.1.7997545
Becker S, Lepareur N, Cadeillan V, et al. Optimization of hepato-carcinoma uptake with radiolabeled lipiodol: development of new lipiodol formulations with increased viscosity. Cancer Biother Radiopharm. 2012;27:149–55.
doi: 10.1089/cbr.2011.1072
Kan Z, Wright K, Wallace S. Ethiodized oil emulsions in hepatic microcirculation: in vivo microscopy in animal models. Acad Radiol. 1997;4:275–82.
doi: 10.1016/S1076-6332(97)80029-3
Idée JM, Guiu B. Use of lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review. Crit Rev Oncol Hematol. 2013;88:530–49.
doi: 10.1016/j.critrevonc.2013.07.003
Tanaka T, Masada T, Nishiofuku H, et al. Development of pumping emulsification device with glass membrane to form ideal lipiodol emulsion in transarterial chemoembolization. Eur Radiol. 2018;28:2203–7.
doi: 10.1007/s00330-017-5197-x
Masada T, Tanaka T, Nishiofuku H, et al. Use of a glass membrane pumping emulsification device improves systemic and tumor pharmacokinetics in rabbit vx2 liver tumor in transarterial chemoembolization. J Vasc Interv Radiol. 2020;31:347–51.
doi: 10.1016/j.jvir.2019.06.015
Tanaka T, Nishiofuku H, Masada T, et al. Drug release property of lipiodol emulsion formed by glass membrane emulsification device for transarterial chemoembolization. Cardiovasc Interv Radiol. 2020;43:135–9.
doi: 10.1007/s00270-019-02311-9
Masada T, Tanaka T, Nishiofuku H, et al. Techniques to form a suitable lipiodol-epirubicin emulsion by using 3-way stopcock methods in transarterial chemoembolization for liver tumor. J Vasc Interv Radiol. 2017;28:1461–6.
doi: 10.1016/j.jvir.2017.03.032
Nishiofuku H, Tanaka T, Matsuoka M, et al. Transcatheter arterial chemoembolization using cisplatin powder mixed with degradable starch microspheres for colorectal liver metastases after FOLFOX failure: results of a phase I/II study. J Vasc Interv Radiol. 2013;24:56–65.
doi: 10.1016/j.jvir.2012.09.010
Sato T, Tanaka T, Nishiofuku H, et al. Pharmacokinetics and histopathological findings of chemoembolization using cisplatin powder mixed with degradable starch microspheres in a rabbit liver tumor model. Cardiovasc Interv Radiol. 2017;40:438–44.
doi: 10.1007/s00270-016-1512-1
Sato T, Tanaka T, Nishiofuku H, et al. Superabsorbent polymer microspheres prepared with hypertonic saline to reduce microsphere expansion. Cardiovasc Interv Radiol. 2018;41:1412–8.
doi: 10.1007/s00270-018-1990-4
Pickering EC. Emulsion. J Chem Soc. 1907;91:2001–21.
doi: 10.1039/CT9079102001
Ramsden W. Separation of solids in the surface-layers of solutions and ‘suspension’ (observations on surface-membranes, bubbles, emulsions, and mechanical coagulation) preliminary account. Proc R Soc Lond. 1903;72:156–64.
Deschamps F, Harris KR, Moine L, et al. Pickering-emulsion for liver trans-arterial chemo-embolization with oxaliplatin. Cardiovasc Interv Radiol. 2018;41:781–8.
doi: 10.1007/s00270-018-1899-y
Wang A, Xiao Z, Wang J, Li G, Wang L. Fabrication and characterization of emulsion stabilized by table egg-yolk granules at different pH levels. J Sci Food Agric. 2020;100:1470–8.
doi: 10.1002/jsfa.10154
Hosseini RS, Rajaei A. Potential Pickering emulsion stabilized with chitosan-stearic acid nanogels incorporating clove essential oil to produce fish-oil-enriched mayonnaise. Carbohydr Polym. 2020;241:116340.
doi: 10.1016/j.carbpol.2020.116340
Higashi S, Tabata N, Kondo KH, et al. Size of lipid microdroplets effects results of hepatic arterial chemotherapy with an anticancer agent in water-in-oil-in-water emulsion to hepatocellular carcinoma. J Pharmacol Exp Ther. 1999;289:816–9.
pubmed: 10215657
Hasegawa T, Takaki H, Yamanaka T, et al. Experimental assessment of temperature influence on miriplatin and cisplatin iodized-oil suspension viscosity. Jpn J Radiol. 2013;31:424–7.
doi: 10.1007/s11604-013-0201-0
Koizumi Y, Hirooka M, Uehara T, et al. Transcatheter arterial chemoembolization with fine-powder cisplatin-lipiodol for HCC. Hepatogastroenterology. 2011;58:512–5.
pubmed: 21661422
Yodono H, Matsuo K, Shinohara A. A retrospective comparative study of epirubicin-lipiodol emulsion and cisplatin-lipiodol suspension for use with transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma. Anticancer Drugs. 2011;22:277–82.
doi: 10.1097/CAD.0b013e328342231d
Takaki Y, Kaminou T, Shabana M, et al. Suitable blending method of lipiodol-cisplatin in transcatheter arterial embolization for hepatocellular carcinoma: evaluation of sustained release and accumulation nature. Hepatogastroenterology. 2008;55:202–6.
pubmed: 18507107
Mine T, Murata S, Ueda T, et al. Comparative study of cisplatin-iodized oil suspension and emulsion for transcatheter arterial chemoembolization of rabbit VX2 liver tumors. Hepatol Res. 2012;42:473–81.
doi: 10.1111/j.1872-034X.2011.00942.x
Nakano M, Niizeki T, Nagamatsu H, et al. Clinical effects and safety of intra-arterial infusion therapy of cisplatin suspension in lipiodol combined with 5-fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra-hepatic spread: a prospective cohort study. Mol Clin Oncol. 2017;7:1013–20.
pubmed: 29285366
pmcid: 5740831
Nagamatsu H, Sumie S, Niizeki T, et al. Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study. Cancer Chemother Pharmacol. 2016;77:243–50.
doi: 10.1007/s00280-015-2892-7
Shen DW, Akiyama S, Schoenlein P, et al. Characterisation of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: cross resistance. and protein changes. Br J Cancer. 1995;71:676–83.
doi: 10.1038/bjc.1995.134